Baird analyst Brian Skorney reiterated an Outperform rating and $33.00 price target on Nurix (NASDAQ: NRIX).The analyst comments "No change ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Hot Comments

Nurix (NRIX) PT Raised to $40 at StifelJuly 10, 2026 7:38 AM Nurix (NRIX) PT Raised to $33 at RBC Capital; 'I&I Opportunities Remain Underappreciated'July 10, 2026 7:30 AM Nurix (NRIX) PT Raised at Truist Securities; 'Roche Partnership Broadens Path to Value Creation'July 10, 2026 7:04 AM Nurix (NRIX) PT Raised to $34 at H.C. WainwrightJuly 10, 2026 6:50 AM Form 10-Q Nurix Therapeutics, Inc. For: May 31July 9, 2026 4:12 PM Form 8-K Nurix Therapeutics, Inc. For: Jul 09July 9, 2026 4:10 PM Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateJuly 9, 2026 4:01 PM